Logo

Vela Diagnostics Receives CE-IVD Mark for Cell-Free DNA Kit

Nov 30, 2017 | staff reporter

NEW YORK (GenomeWeb) – Vela Diagnostics said today that its Sentosa SX Cell-free DNA Kit is now CE marked for in vitro diagnostics use.

The kit is designed to run on the Sentosa SX101 instrument, and enables extraction of circulating cfDNA from human plasma, for use in next-gen sequencing and real-time PCR workflows.

According to Vela, its technology has a high recovery efficiency for DNA fragments of about 170bp, and allows the recovery of low-frequency variants. Automated sample extraction takes approximately 3.5 hours with 20 minutes of operator hands-on time.

Vela doesn't currently offer PCR or NGS assays that are specifically validated for cell-free DNA, but the company said that various workflows that have been validated for IVD use in FFPE samples are now pending a cfDNA claim extension.

Filed under

Cancer
Molecular Diagnostics
Liquid Biopsy
CE mark
cell-free DNA
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.